JMP Securities Downgrades Edge Therapeutics (EDGE) to Market Perform, 'Phase 3 NEWTON 2 trial failed to showbenefit with EG-1962'
Tweet Send to a Friend
JMP Securities downgraded Edge Therapeutics (NASDAQ: EDGE) from Market ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
